MilliporeSigma acquires AmpTec

By The Science Advisory Board staff writers

MilliporeSigma has purchased messenger RNA (mRNA) firm AmpTec. The deal is expected to boost MilliporeSigma's ability to develop and manufacture mRNA for use in COVID-19 vaccines and treatments.

AmpTec's polymerase chain reaction (PCR)-based technology has benefits over other technologies for mRNA manufacturing, including better homogeneity, purity, and activity and improved performance, according to MilliporeSigma. As well, AmpTec's diagnostics business, which produces customized long RNAs and DNAs for in vitro diagnostics, will complement MilliporeSigma's own diagnostics business, it said.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking